- The study represents the largest real-world evaluation of
stroke artificial intelligence (AI) imaging, involving more than
80,000 patients at 26 sites over a 3-year period.
- The results showed Brainomix 360 Stroke was associated
with an additional 50% increase in the number of patients receiving
mechanical thrombectomy, while also improving the speed of
treatment by 49 minutes.
OXFORD, England and
CHICAGO, May 15, 2024 /PRNewswire/ -- Results from the
largest prospective study of stroke AI software were presented
today at the European Stroke Organisation Conference (ESOC) in
Basel, showing that the
implementation of Brainomix 360 Stroke was associated with a 50%
greater increase in the number of patients receiving mechanical
thrombectomy. Mechanical thrombectomy is a life-changing stroke
treatment which can reduce disability and prevent or limit
long-term care needs in patients with the most severe strokes due
to blockage of a large blood vessel supplying the brain.
The study stemmed from an independent evaluation of Brainomix
360 Stroke commissioned by the UK government across five stroke
networks over 3 years to determine the real-world impact of AI
technology. The analysis, led by Health Innovation (HIN)
Oxford & Thames Valley, was
conducted using patient-level and site-level data from the Sentinel
Stroke National Audit Programme (SSNAP), including more than 83,000
individual stroke patient data from the 26 sites participating in
the evaluation. When compared against site-level data from 73 UK
hospitals not included in the AI award, the results showed the rate
of mechanical thrombectomy rose by 115% at evaluation sites, 50%
higher than the increase observed at non-evaluation sites
(65%).
Dr Kiruba Nagaratnam,
Consultant Stroke Physician and Clinical Lead for Stroke Medicine
at the Royal Berkshire NHS Foundation Trust, was the lead author of
the study and presented the results Wednesday afternoon at ESOC.
"This study is the largest real-world evaluation of stroke AI
software, with more than 80,000 patients assessed over a 3-year
period. The results showed that the introduction of Brainomix 360
Stroke reduced the door-in-door-out (DIDO) time by 49 minutes – and
notably, was associated with a significant increase in the number
of patients receiving mechanical thrombectomy. These are very
powerful results and show that the large-scale implementation of
the Brainomix software as a component of a collaborative model
of care in stroke networks is feasible and is associated with
increasing access to mechanical thrombectomy treatment."
Dr George Harston, Chief
Medical & Innovation Officer at Brainomix and Consultant Stroke
Physician at Oxford University
Hospitals NHS Foundation Trust, said: "We are delighted to see the
dramatic increase in stroke treatment numbers and improved
treatment times across multiple stroke networks in England following the implementation of
Brainomix 360 Stroke. This is the largest study of stroke AI
software ever undertaken, and the results not only validate the
generalisability of the findings we have seen in single-site
studies, but also reflect the comprehensive nature of the Brainomix
360 Stroke platform, which uniquely delivers value to both primary
and comprehensive stroke centers.
"We estimate that if the same increase on thrombectomy had been
seen across the whole NHS in England, in a single calendar year the cost
savings to the UK economy would be around £30 million.
"We would like to thank the Oxford HIN and NHS Accelerated
Access Collaborative (AAC) for their robust evaluation and support,
and to all the hospital teams and patients who collaborated in this
landmark research study."
This latest study builds on a growing body of evidence
validating the impact of Brainomix's stroke AI imaging platform,
including a study published earlier this year in Frontiers
in Neurology1 which showed that the
implementation of Brainomix 360 Stroke at the Royal Berkshire
Hospital improved patient outcomes, trebling the number of stroke
patients achieving functional independence from 16% to 48%.
1 Nagaratnam K et al. Artificial
intelligence-based decision support software to improve the
efficacy of acute stroke pathway in the NHS: an observational
study. Frontiers in Neurology. 2024;14
About Brainomix
Brainomix specializes in the creation of AI-powered software
solutions to enable precision medicine for better treatment
decisions in stroke and lung fibrosis. With origins as a spin-out
from the University of Oxford, Brainomix is an expanding
commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 30 countries.
A private company, backed by leading healthtech investors,
Brainomix has innovated award-winning imaging biomarkers and
software solutions that have been clinically adopted in hundreds of
hospitals worldwide. Its first product, the Brainomix 360 stroke
platform, provides clinicians with the most comprehensive stroke
imaging solution, driving increased treatment rates and improving
functional independence for patients.
To learn more about Brainomix and its technology
visit www.brainomix.com, and follow us
on Twitter, LinkedIn and Facebook.
Contacts
Jeff Wyrtzen,
Chief Marketing & Business Development Officer
jwyrtzen@brainomix.com
M +44 (0)7927 164210
T +44 (0)1865 582730
Media Enquiries
Charles Consultants
Sue Charles
Sue@charles-consultants.com
M +44 (0)7968 726585
Logo -
https://mma.prnewswire.com/media/1989193/4705195/Brainomix_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.co.uk/news-releases/new-study-shows-brainomix-360-ai-transforms-stroke-treatment-in-england-302146196.html